Please login to view this media
- Talk
- UK
30 Day Mortality Following Surgical Management of Hip Fractures during the COVID-19 Pandemic: Findings from a Prospective Multi-centre UK Study
Description
In this presentation led by Ashish Narang, the discussion focuses on a prospective multicenter study examining 30-day mortality rates following surgical management of hip fractures during the COVID-19 pandemic. The study was conducted across nine hospitals in the South and Southeast of England, particularly highlighting the challenges posed by the pandemic amidst a significant surge in COVID-19 cases and related healthcare guidelines.
Ashish Narang introduces the study's objective, aiming to assess the 30-day mortality in hip fracture patients, noting that the incidence of such fractures remained high even as elective surgeries were postponed. The presentation compares cohorts of COVID-positive patients with COVID-negative ones and also includes a time-matched cohort from the previous year for control. Throughout the investigation, several key metrics were evaluated, including demographics, time to surgery, and mortality rates associated with each cohort.
The study found that patients with COVID-19 experiencing hip fractures had notably higher mortality rates than expected based on their Nottingham hip fracture scores, while no significant difference in mortality was observed within the COVID-negative cohort compared to the 2019 controls. Additionally, the Kaplan-Meier survivorship analysis reflected stark differences in outcomes based on COVID-19 status.
Narang concludes that COVID-positive patients have a threefold higher mortality risk and emphasizes the priority of surgical intervention for these patients. Special considerations to prevent COVID transmission during treatment are also outlined, along with an acknowledgment of limitations within the data collection process. The discussions shift towards addressing questions from the audience relating to causes of death and patient admission origins.